Company profile

Sequana Medical is a commercial stage company specialized in the development of medical devices for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. In particular, the group offers the alfapumpĀ®, a fully implantable, programmable system with CE mark for the management of refractory ascites (chronic accumulation of fluid in the abdomen) due to cirrhosis of the liver, and malignant ascites (with a life expectancy of six months or less). Sequana Medical is also developing alfapumpĀ® DSR, a novel and proprietary approach to the treatment of volume overload in heart failure.

Source: Cofisem - Last Update: 21 Jun 2019
Key Executives
Chief Executive Officer Ian Crosbie
Chief Financial Officer Kirsten Van Bockstaele
Investor Relations Lies Vanneste
Source: Cofisem - Last Update: 21 Jun 2019
Key figures
Millenium 2018 2017 2016 2015
Net sales 1.029 1.304 1.489 1.685
Income from ordinary activities 1.029 1.304 1.489 1.685
Operating income -13.077 -7.418 -13.945 -11.356
Cost (net) of financial indebtedness -922 -635 -187 -84
Equity-accounted companies' contribution to results
Net profit from discontinued activities
Net income -13.983 -8.225 -13.975 -11.557
Net income (Group share) -13.983 -8.225 -13.975 -11.557
Fiscal year end 12,18 12,17 12,16 12,15
Length of fiscal year (month) 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 21 Jun 2019
Shareholder information
NeoMed 33,00 %
Free float 18,00 %
LSP Health Economics Fund Management B.V. 12,00 %
PMV 10,00 %
FPIM 9,00 %
Newton Biocapital 9,00 %
Venture Incubator AG 4,00 %
Capricorn Health-Tech Fund NV 1,52 %
Source: Cofisem - Last Update: 07 May 2019

Address

Sequana Medical

Technologiepark 122
BE-9052 Zwijnaarde, Gent, Oost-Vlaanderen
Belgium
Phone number: +32 9 292 8065
Fax: +32
Source: Cofisem - Last Update: 21 Jun 2019

Contact

Lies Vanneste
Phone number: +32 498 053579
Source: Cofisem - Last Update: 21 Jun 2019